These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

658 related items for PubMed ID: 25904506

  • 1. IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors.
    Ab O, Whiteman KR, Bartle LM, Sun X, Singh R, Tavares D, LaBelle A, Payne G, Lutz RJ, Pinkas J, Goldmacher VS, Chittenden T, Lambert JM.
    Mol Cancer Ther; 2015 Jul; 14(7):1605-13. PubMed ID: 25904506
    [Abstract] [Full Text] [Related]

  • 2. Folate Receptor α-Targeted 89Zr-M9346A Immuno-PET for Image-Guided Intervention with Mirvetuximab Soravtansine in Triple-Negative Breast Cancer.
    Heo GS, Detering L, Luehmann HP, Primeau T, Lee YS, Laforest R, Li S, Stec J, Lim KH, Lockhart AC, Liu Y.
    Mol Pharm; 2019 Sep 03; 16(9):3996-4006. PubMed ID: 31369274
    [Abstract] [Full Text] [Related]

  • 3. Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models.
    Ponte JF, Ab O, Lanieri L, Lee J, Coccia J, Bartle LM, Themeles M, Zhou Y, Pinkas J, Ruiz-Soto R.
    Neoplasia; 2016 Dec 03; 18(12):775-784. PubMed ID: 27889646
    [Abstract] [Full Text] [Related]

  • 4. In Vitro and In Vivo Activity of IMGN853, an Antibody-Drug Conjugate Targeting Folate Receptor Alpha Linked to DM4, in Biologically Aggressive Endometrial Cancers.
    Altwerger G, Bonazzoli E, Bellone S, Egawa-Takata T, Menderes G, Pettinella F, Bianchi A, Riccio F, Feinberg J, Zammataro L, Han C, Yadav G, Dugan K, Morneault A, Ponte JF, Buza N, Hui P, Wong S, Litkouhi B, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, Santin AD.
    Mol Cancer Ther; 2018 May 03; 17(5):1003-1011. PubMed ID: 29440294
    [Abstract] [Full Text] [Related]

  • 5. Design of Coltuximab Ravtansine, a CD19-Targeting Antibody-Drug Conjugate (ADC) for the Treatment of B-Cell Malignancies: Structure-Activity Relationships and Preclinical Evaluation.
    Hong EE, Erickson H, Lutz RJ, Whiteman KR, Jones G, Kovtun Y, Blanc V, Lambert JM.
    Mol Pharm; 2015 Jun 01; 12(6):1703-16. PubMed ID: 25856201
    [Abstract] [Full Text] [Related]

  • 6. MEN1309/OBT076, a First-In-Class Antibody-Drug Conjugate Targeting CD205 in Solid Tumors.
    Merlino G, Fiascarelli A, Bigioni M, Bressan A, Carrisi C, Bellarosa D, Salerno M, Bugianesi R, Manno R, Bernadó Morales C, Arribas J, Dusek RL, Ackroyd JE, Pham PH, Awdew R, Aud D, Trang M, Lynch CM, Terrett J, Wilson KE, Rohlff C, Manzini S, Pellacani A, Binaschi M.
    Mol Cancer Ther; 2019 Sep 01; 18(9):1533-1543. PubMed ID: 31227646
    [Abstract] [Full Text] [Related]

  • 7. Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study.
    Moore KN, Martin LP, O'Malley DM, Matulonis UA, Konner JA, Perez RP, Bauer TM, Ruiz-Soto R, Birrer MJ.
    J Clin Oncol; 2017 Apr 01; 35(10):1112-1118. PubMed ID: 28029313
    [Abstract] [Full Text] [Related]

  • 8. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity.
    Ogitani Y, Hagihara K, Oitate M, Naito H, Agatsuma T.
    Cancer Sci; 2016 Jul 01; 107(7):1039-46. PubMed ID: 27166974
    [Abstract] [Full Text] [Related]

  • 9. MORAb-202, an Antibody-Drug Conjugate Utilizing Humanized Anti-human FRα Farletuzumab and the Microtubule-targeting Agent Eribulin, has Potent Antitumor Activity.
    Cheng X, Li J, Tanaka K, Majumder U, Milinichik AZ, Verdi AC, Maddage CJ, Rybinski KA, Fernando S, Fernando D, Kuc M, Furuuchi K, Fang F, Uenaka T, Grasso L, Albone EF.
    Mol Cancer Ther; 2018 Dec 01; 17(12):2665-2675. PubMed ID: 30262588
    [Abstract] [Full Text] [Related]

  • 10. AMG 595, an Anti-EGFRvIII Antibody-Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII-Expressing Glioblastoma.
    Hamblett KJ, Kozlosky CJ, Siu S, Chang WS, Liu H, Foltz IN, Trueblood ES, Meininger D, Arora T, Twomey B, Vonderfecht SL, Chen Q, Hill JS, Fanslow WC.
    Mol Cancer Ther; 2015 Jul 01; 14(7):1614-24. PubMed ID: 25931519
    [Abstract] [Full Text] [Related]

  • 11. Anetumab ravtansine: a novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effect.
    Golfier S, Kopitz C, Kahnert A, Heisler I, Schatz CA, Stelte-Ludwig B, Mayer-Bartschmid A, Unterschemmann K, Bruder S, Linden L, Harrenga A, Hauff P, Scholle FD, Müller-Tiemann B, Kreft B, Ziegelbauer K.
    Mol Cancer Ther; 2014 Jun 01; 13(6):1537-48. PubMed ID: 24714131
    [Abstract] [Full Text] [Related]

  • 12. Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates.
    Erickson HK, Widdison WC, Mayo MF, Whiteman K, Audette C, Wilhelm SD, Singh R.
    Bioconjug Chem; 2010 Jan 01; 21(1):84-92. PubMed ID: 19891424
    [Abstract] [Full Text] [Related]

  • 13. Effects of Drug-Antibody Ratio on Pharmacokinetics, Biodistribution, Efficacy, and Tolerability of Antibody-Maytansinoid Conjugates.
    Sun X, Ponte JF, Yoder NC, Laleau R, Coccia J, Lanieri L, Qiu Q, Wu R, Hong E, Bogalhas M, Wang L, Dong L, Setiady Y, Maloney EK, Ab O, Zhang X, Pinkas J, Keating TA, Chari R, Erickson HK, Lambert JM.
    Bioconjug Chem; 2017 May 17; 28(5):1371-1381. PubMed ID: 28388844
    [Abstract] [Full Text] [Related]

  • 14. A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies.
    Deckert J, Park PU, Chicklas S, Yi Y, Li M, Lai KC, Mayo MF, Carrigan CN, Erickson HK, Pinkas J, Lutz RJ, Chittenden T, Lambert JM.
    Blood; 2013 Nov 14; 122(20):3500-10. PubMed ID: 24002446
    [Abstract] [Full Text] [Related]

  • 15. Antibody-drug conjugates for ovarian cancer: current clinical development.
    Stewart D, Cristea M.
    Curr Opin Obstet Gynecol; 2019 Feb 14; 31(1):18-23. PubMed ID: 30531606
    [Abstract] [Full Text] [Related]

  • 16. Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α-targeting antibody-drug conjugate, in patients with solid tumors.
    Moore KN, Borghaei H, O'Malley DM, Jeong W, Seward SM, Bauer TM, Perez RP, Matulonis UA, Running KL, Zhang X, Ponte JF, Ruiz-Soto R, Birrer MJ.
    Cancer; 2017 Aug 15; 123(16):3080-3087. PubMed ID: 28440955
    [Abstract] [Full Text] [Related]

  • 17. Leveraging PET to image folate receptor α therapy of an antibody-drug conjugate.
    Brand C, Sadique A, Houghton JL, Gangangari K, Ponte JF, Lewis JS, Pillarsetty NVK, Konner JA, Reiner T.
    EJNMMI Res; 2018 Aug 28; 8(1):87. PubMed ID: 30155674
    [Abstract] [Full Text] [Related]

  • 18. Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer.
    O'Malley DM, Matulonis UA, Birrer MJ, Castro CM, Gilbert L, Vergote I, Martin LP, Mantia-Smaldone GM, Martin AG, Bratos R, Penson RT, Malek K, Moore KN.
    Gynecol Oncol; 2020 May 28; 157(2):379-385. PubMed ID: 32081463
    [Abstract] [Full Text] [Related]

  • 19. Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FRα-targeting antibody-drug conjugate mirvetuximab soravtansine.
    Martin LP, Konner JA, Moore KN, Seward SM, Matulonis UA, Perez RP, Su Y, Berkenblit A, Ruiz-Soto R, Birrer MJ.
    Gynecol Oncol; 2017 Nov 28; 147(2):402-407. PubMed ID: 28843653
    [Abstract] [Full Text] [Related]

  • 20. Biological evaluation of antibody-maytansinoid conjugates as a strategy of RON targeted drug delivery for treatment of non-small cell lung cancer.
    Feng L, Yao HP, Zhou YQ, Zhou J, Zhang R, Wang MH.
    J Exp Clin Cancer Res; 2016 Apr 22; 35():70. PubMed ID: 27102688
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.